The Differentiation of Yeast and Yeast-Like Fungi

Total Page：16

File Type：pdf, Size：1020Kb

The Differentiation of Yeast and Yeast-Like Fungi

3/28/2017 Disclosure of Relevant The Differentiation of Yeast Financial Relationships USCAP requires that all planners (Education Committee) in a position to and Yeast-Like Fungi influence or control the content of CME disclose any relevant financial relationship WITH COMMERCIAL INTERESTS which they or their Gary W. Procop, MD, MS spouse/partner have, or have had, within the past 12 months, which relates to the content of this educational activity and creates a conflict of interest. Dr. Gary W. Procop declares he/she has no conflict(s) of interest to disclose. What are the Possibilities? The Inflammatory Response How to Limit the Differential? • Neutrophilic • Candida species • These may be: • Allergic Reaction • Bronchopulmonary Aspergillosis and Allergic Fungal Sinusitis • Yeast • Granulomas • With/without necrosis • Dimorphic Fungi • Coccidioides, Histoplasma, Cryptococcus • With eosinophils • Dematiaceous Fungi • Coccidioides • Pyogranulomatous • Sporothrix, Blastomyces, Agents of Chromoblastomycosis • Chronic • Differentiate Morphologically • Blastomyces • Based on size, morphology, special features • Immunosupression • Truncated Responses • Poorly formed granulomas • Lack of typical cellular elements • Culture Definitively Differentiates • Example: Histoplasma in histiocytes rather than granulomas. • Reaction to injury • Necrosis, hyaline membrane disease, etcetera. Small Yeast Forms (2-4 microns) • Histoplasma capsulatum • Sporothrix schenckii complex • C. glabrata, • Malassezia species • Pneumocystis jirovecii • Endospores of C. immitis • “Acapsular variants of C. neoformans. • Talaromyces (Penicillium) marneffei 1 3/28/2017 Histoplasma capsulatum Sporothrix schenckii complex C. glabrata, C. tropicalis and a Zygomycete Malassezia species 2 3/28/2017 Pneumocystis jirovecii Talaromyces (Penicillium) marneffei Moderate and Large Yeast Forms • Moderate (4-10 microns) • Candida species other than C. glabrata. • Cryptococcus • Immature spherules of C. immitis • Dematiaceous Fungi • Exophiala species • Agents of Chromoblastomycosis • Large (>10 microns) • Blastomyces dermatitidis • Spherule of C. immitis 3 3/28/2017 Exophiala - Young Exophiala with Age Chromoblastomycosis • Chronic fungal disease that involves the skin and subcutaneous tissues. • Causes pyogranulomatous inflammatory response, pseudoepitheliomatous hyperplasia, and the Splendore-Hoeppli phenomenon may be observed. • Fungal elements (sclerotic bodies) appear as “copper pennies” • Common causes: Cladosporium (Cladophialophora), Phialophora, Fonsecaea. 4 3/28/2017 5 3/28/2017 Optimal Use of Molecular Tools ** Engage a Pathologist ** • 17 month compared 100 patient specimens • Broad Range Fungal PCR • Direct Examination (KOH/Calcofluor White) • Fungal Culture • Histopathology 6 3/28/2017 Important Information Regarding CME/SAMs The Online CME/Evaluations/SAMs claim process will only be available on the USCAP website until September 30, 2017. No claims can be processed after that date! After September 30, 2017 you will NOT be able to obtain any CME or SAMs credits for attending this meeting. 7.

Copy Link

Recommended publications

Obligate Biotrophs of Humans and Other Mammals
Pearls Genomic Insights into the Fungal Pathogens of the Genus Pneumocystis: Obligate Biotrophs of Humans and Other Mammals Philippe M. Hauser* Institute of Microbiology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland Pneumocystis organisms were first believed to be a single telomeres were not assembled. The nuclear genomes of the three protozoan species able to colonize the lungs of all mammals. Pneumocystis spp. are approximately 8 Mb. Subsequently, genetic analyses revealed their affiliation to the The mitochondrial genomes of P. murina and P. carinii are fungal Taphrinomycotina subphylum of the Ascomycota, a clade approximately 25 kb, whereas that of P. jirovecii is around 35 kb which encompasses plant pathogens and free-living yeasts. It also (Table 1). This size difference is due to a supplementary region that is appeared that, despite their similar morphological appearance, non-coding and highly variable in size and sequence among isolates these fungi constitute a family of relatively divergent species, each [5]. The circular structure of the P. jirovecii mitochondrial genome with a strict specificity for a unique mammalian species [1]. The differs from the linear one present in the two other Pneumocystis spp. species colonizing human lungs, Pneumocystis jirovecii, can turn The biological significance of this difference remains unknown. into an opportunistic pathogen that causes Pneumocystis pneu- monia (PCP) in immunocompromised individuals, a disease which Genome Content may be fatal. Although the incidence of PCP diminished in the 1990s thanks to prophylaxis and antiretroviral therapy, PCP is Using gene models specifically developed, the three Pneumo- nowadays the second-most-frequent, life-threatening, invasive cystis spp.
[Show full text]
1. Economic, Ecological and Cultural Importance of Fungi
1. Economic, ecological and cultural importance of Fungi Fungi as food Yeast fermentations, Saccaromyces cerevesiae [Ascomycota] alcoholic beverages, yeast leavened bread Glucose 2 glyceraldehyde-3-phosphate + 2 ATP 2 NAD O2 2 NADH2 2 pyruvate + 2 ATP + 2 H2O 2 ethanol 2 acetaldehyde + 2 ATP + 2 CO2 Fungi as food Citric acid Aspergillus niger Fungi as food Cheese Penicillium camembertii, Penicillium roquefortii Rennet, chymosin produced by Rhizomucor miehei and recombinant Aspergillus niger, Saccharomyces cerevesiae chymosin first GM enzyme approved for use in food Fungi as food Quorn mycoprotein, produced from biomass of Fusarium venenatum [Ascomycota] Fungi as food Red yeast rice, Monascus purpureus Soy fermentations, Aspergillus oryzae [Ascomycota] contains lovastatin? Tempeh, made with Rhizopus oligosporus [Zygomycota] Fungi as food Other fungal food products: vitamins and enzymes • vitamins: riboflavin (vitamin B2), commercially produced by Ashbya gossypii • chocolate: cacao beans fermented before being made into chocolate with a mixture of yeasts and filamentous fungi: Candida krusei, Geotrichum candidum, Hansenula anomala, Pichia fermentans • candy: invertase, commercially produced by Aspergillus niger, various yeasts, enzyme splits disaccharide sucrose into glucose and fructose, used to make candy with soft centers • glucoamylase: Aspergillus niger, used in baking to increase fermentable sugar, also a cause of “baker’s asthma” • pectinases, proteases, glucanases for clarifying juices, beverages Fungi as food Perigord truffle, Tuber
[Show full text]
Pneumocystis Pneumonia: Immunity, Vaccines, and Treatments
pathogens Review Pneumocystis Pneumonia: Immunity, Vaccines, and Treatments Aaron D. Gingerich 1,2, Karen A. Norris 1,2 and Jarrod J. Mousa 1,2,* 1 Center for Vaccines and Immunology, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA; [email protected] (A.D.G.); [email protected] (K.A.N.) 2 Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA * Correspondence: [email protected] Abstract: For individuals who are immunocompromised, the opportunistic fungal pathogen Pneumocystis jirovecii is capable of causing life-threatening pneumonia as the causative agent of Pneumocystis pneumonia (PCP). PCP remains an acquired immunodeficiency disease (AIDS)-defining illness in the era of antiretroviral therapy. In addition, a rise in non-human immunodeficiency virus (HIV)-associated PCP has been observed due to increased usage of immunosuppressive and im- munomodulating therapies. With the persistence of HIV-related PCP cases and associated morbidity and mortality, as well as difficult to diagnose non-HIV-related PCP cases, an improvement over current treatment and prevention standards is warranted. Current therapeutic strategies have pri- marily focused on the administration of trimethoprim-sulfamethoxazole, which is effective at disease prevention. However, current treatments are inadequate for treatment of PCP and prevention of PCP-related death, as evidenced by consistently high mortality rates for those hospitalized with PCP. There are no vaccines in clinical trials for the prevention of PCP, and significant obstacles exist that have slowed development, including host range specificity, and the inability to culture Pneumocystis spp. in vitro. In this review, we overview the immune response to Pneumocystis spp., and discuss current progress on novel vaccines and therapies currently in the preclinical and clinical pipeline.
[Show full text]
Mucormycosis of the Central Nervous System
Journal of Fungi Review Mucormycosis of the Central Nervous System 1 1,2, , 3, , Amanda Chikley , Ronen Ben-Ami * y and Dimitrios P Kontoyiannis * y 1 Infectious Diseases Unit, Tel Aviv Sourasky Medical Center, Tel Aviv 64239, Israel 2 Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 64239, Israel 3 Department of Infectious Diseases, The University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030, USA * Correspondence: [email protected] (R.B.-A.); [email protected] (D.P.K.) These authors contribute equally to this paper. y Received: 6 June 2019; Accepted: 7 July 2019; Published: 8 July 2019 Abstract: Mucormycosis involves the central nervous system by direct extension from infected paranasal sinuses or hematogenous dissemination from the lungs. Incidence rates of this rare disease seem to be rising, with a shift from the rhino-orbital-cerebral syndrome typical of patients with diabetes mellitus and ketoacidosis, to disseminated disease in patients with hematological malignancies. We present our current understanding of the pathobiology, clinical features, and diagnostic and treatment strategies of cerebral mucormycosis. Despite advances in imaging and the availability of novel drugs, cerebral mucormycosis continues to be associated with high rates of death and disability. Emerging molecular diagnostics, advances in experimental systems and the establishment of large patient registries are key components of ongoing eﬀorts to provide a timely diagnosis and eﬀective treatment to patients with cerebral mucormycosis. Keywords: central nervous system; mucormycosis; Mucorales; zygomycosis 1. Introduction Mucormycosis is the second most frequent invasive mold disease after aspergillosis [1–3], with rising incidence reported in some countries [4–7].
[Show full text]
GAFFI Fact Sheet Pneumocystis Pneumonia
OLD VERSION GLOBAL ACTION FUNDGAL FOR INFECTIONS FUN GAFFI Fact Sheet Pneumocystis pneumonia GLOBAL ACTION FUNDGAL FOR INFECTIONS Pneumocystis pneumonia (PCP) is a life-threatening illness of largely FUN immunosuppressed patients such as those with HIV/AIDS. However, when diagnosed rapidly and treated, survival rates are high. The etiologic agent of PCP is DARKER AREAS AND SMALLER VERSION TEXT FIT WITHIN CIRCLE (ALSO TO BE USED AS MAIN Pneumocystis jirovecii, a human only fungus that has co-evolved with humans. Other LOGO IN THE FUTURE) mammals have their own Pneumocystis species. Person to person transmission occurs early in life as demonstrated by antibody formation in infancy and early childhood. Some individuals likely clear the fungus completely, while others become carriers of variable intensity. About 20% of adults are colonized but higher colonization rates occur in children and immunosuppressed adults; ethnicity and genetic associations with colonization are poorly understood. Co-occurrence of other respiratory infections may provide the means of transmission in most instances. Patients with Pneumocystis pneumonia (PCP) are highly infectious. Prophylaxis with oral cotrimoxazole is highly effective in preventing infection. Pneumocystis pneumonia The occurrence of fatal Pneumocystis pneumonia in homosexual men in the U.S. provided one of earliest signals of the impending AIDS epidemic in the 1980s. Profound immunosuppression, especially T cell depletion and dysfunction, is the primary risk group for PCP. Early in the AIDS epidemic, PCP was the AIDS-defining diagnosis in ~60% of individuals. This frequency has fallen in the western world, but infection is poorly documented in most low-income countries because of the lack of diagnostic capability.
[Show full text]
HIV Awareness in the Workplace Online Nursing CE Course
Online Continuing Education for Nurses Linking Learning to Performance INSIDE THIS COURSE HIV AIDS 7 UNIT: HIV AWARENESS COURSE OUTLINE ............................ 2 IN THE WORKPLACE CHAPTER 1: HIV AIDS DEFINED ...... 3 CHAPTER 2: WORKPLACE 7.0 Contact Hours PROTECTION ................................. 11 0.7 Continuing Education Units CHAPTER 3: PATIENT CARE AND RIGHTS ......................................... 14 Written by: Robert Dunham, RMA CHAPTER 4: TUBERCULOSIS ........... 21 Objectives REFERENCES ................................ 29 CE EXAM...................................... 31 After completing HIV Awareness in the EVALUATION ................................. 38 Workplace, you will be able to: 1. Define HIV/AIDS including origin, etiology and epidemiology of HIV. 2. Understand how HIV/AIDS is transmitted and effective methods of infection control and prevention. 3. Discuss contamination myths and practice safe workplace habits to minimize workplace exposure. 4. Identify legal/ethical issues and patient rights surrounding HIV/AIDS. 5. Support patients with HIV/AIDS by providing accurate information and counseling when necessary. 6. Identify tuberculosis and how it impacts immune compromised patients. 7. Understand how medical facilities are taking steps to prevent tuberculosis in the workplace. 8. Understand how the World Health Organization is helping HIV patients with tuberculosis around the world, and how it impacts new defensive medicine techniques. Robert Dunham, RMA www.corexcel.com Page 2 HIV Awareness in the Workplace COURSE OUTLINE I. Etiology and epidemiology of HIV 1. Etiology 2. Reported AIDS cases in the United States and Washington State 3. Risk populations/behaviors II. Transmission and infection control 1. Transmission of HIV 2. Infection Control Precautions 3. Factors affecting risk for transmission 4. Risks for transmission to health care worker III. Testing and counseling 1.
[Show full text]
Opportunistic Infections Moorine Sekadde, Mbchb Heidi Schwarzwald, MD, MPH
HIV Curriculum for the Health Professional Opportunistic Infections Moorine Sekadde, MBchB Heidi Schwarzwald, MD, MPH Objectives Overview 1. Define opportunistic infections (OIs) in people with Many people living with human immunodeficiency virus human immunodeficiency virus (HIV)/AIDS. (HIV)/AIDS acquire diseases that also affect otherwise 2. Describe primary prophylaxis to prevent OIs in healthy people. In such cases, HIV-infected patients people with HIV/AIDS. may have a more severe disease course than uninfected 3. Evaluate the clinical manifestations of bacterial, people or may develop symptoms that uninfected viral, parasitic, and fungal OIs in people with HIV/ people do not. However, HIV-infected people are also AIDS. susceptible to opportunistic infections (OIs), which 4. Describe the treatment for bacterial, viral, parasitic, are infections caused by organisms that in a healthy and fungal OIs in people with HIV/AIDS. host would not cause significant disease. This module 5. Review specific interventions that can decrease the discusses both types of infection. The most common OIs development of OIs in people with HIV/AIDS. vary with geographic location. This module will give a broad overview of the concepts of preventing OIs and Key Points will discuss the most commonly diagnosed diseases worldwide. The module will cover specific diseases, how to 1. An OI is caused by organisms that would not recognize them, and which medicines are recommended produce significant disease in a person with a well- to treat them. Treatment recommendations are based functioning immune system. on available information and research. Not every 2. People with HIV/AIDS are susceptible to OIs because recommendation will be feasible in every setting.
[Show full text]
Jamaica UHSM ¤ 1,2* University Hospital Harish Gugnani , David W Denning of South Manchester NHS Foundation Trust ¤Professor of Microbiology & Epidemiology, St
Burden of serious fungal infections in Jamaica UHSM ¤ 1,2* University Hospital Harish Gugnani , David W Denning of South Manchester NHS Foundation Trust ¤Professor of Microbiology & Epidemiology, St. James School of Medicine, Kralendjik, Bonaire (Dutch Caribbean). 1 LEADING WI The University of Manchester, Manchester Academic Health Science Centre, Manchester, U.K. INTERNATIONAL 2 FUNGAL The University Hospital of South Manchester, (*Corresponding Author) National Aspergillosis Centre (NAC) Manchester, U.K. EDUCATION Background and Rationale The incidence and prevalence of fungal infections in Jamaica is unknown. The first human case of Conidiobolus coronatus infection was discovered in Jamaica (Bras et al. 1965). Cases of histoplasmosis and eumycetoma are reported (Fincharn & DeCeulaer 1980, Nicholson et al., 2004; Fletcher et al, 2001). Tinea capitis is very frequent in children Chronic pulmonary (East-Innis et al., 2006), because of the population being aspergillosis with aspergilloma (in the left upper lobe) in a 53- predominantly of African ancestry. In a one year study of 665 HIV yr-old, HIV-negative Jamaican male, developing after one infected patients, 46% of whom had CD4 cell counts <200/uL, 23 had year of antitubercular treatment; his baseline IgG pneumocystis pneumonia and 3 had cryptococcal meningitis (Barrow titer was 741 mg/L (0-40). As a smoker, he also had moderate et al. 2010). We estimated the burden of fungal infections in Jamaica emphysema. from published literature and modelling. Table 1. Estimated burden of fungal disease in Jamaica Fungal None HIV Respiratory Cancer ICU Total Rate Methods condition /AIDS /Tx burden 100k We also extracted data from published papers on epidemiology and Oesophageal ? 2,100 - ? - 2,100 77 from the WHO STOP TB program and UNAIDS.
[Show full text]
Pneumocystis Pneumonia Jang-Jih Lu,1,2 Chao-Hung Lee3*
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector REVIEW ARTICLE Pneumocystis Pneumonia Jang-Jih Lu,1,2 Chao-Hung Lee3* Pneumocystis pneumonia (PcP) in humans is caused by Pneumocystis jirovecii, which has recently been reclassified as a fungus because its cell wall composition and nucleotide sequences are more similar to those of fungi. PcP occurs only in immunocompromised individuals such as those with AIDS. Despite the use of highly active antiretroviral therapy, PcP remains the leading opportunistic infection in AIDS patients. Based on nucleotide sequence variations in the internal transcribed spacer region of rRNA genes, more than 60 different types of P. jirovecii have been identified. Although type differences do not appear to correlate with the clinical characteristics of PcP, nucleotide sequence variations of the organism have been useful in epidemiologic studies. As a result, some recurrent infections are found to be due to re-infection with new types, and outbreaks due to the same types of P. jirovecii have been identified. Initial diagnosis of PcP is usually based on symptoms and chest radiography. A characteristic histopathologic feature is the presence of acellular eosinophilic exudates and organisms in the alveoli. Ultimate diagnosis of PcP is achieved by demonstration of the organism in induced sputum or bronchoalveolar lavage fluid by tinctorial staining or polymerase chain reaction (PCR). Among the many different PCR methods, the nested PCR that targets the large subunit mitochondrial rRNA gene is the most sensitive and specific. Combination of trimethoprim and sulfamethoxazole is the first choice of drugs for both treatment and prophylaxis of PcP.
[Show full text]
The Relationship Between Pneumocystis Infection in Animal and Human Hosts, and Climatological and Environmental Air Pollution Factors: a Systematic Review
UCSF UC San Francisco Previously Published Works Title The Relationship between Pneumocystis Infection in Animal and Human Hosts, and Climatological and Environmental Air Pollution Factors: A Systematic Review. Permalink https://escholarship.org/uc/item/4b34c3wh Journal OBM genetics, 2(4) ISSN 2577-5790 Authors Miller, Robert F Huang, Laurence Walzer, Peter D Publication Date 2018 DOI 10.21926/obm.genet.1804045 Peer reviewed eScholarship.org Powered by the California Digital Library University of California HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author OBM Genet Manuscript Author . Author manuscript; Manuscript Author available in PMC 2019 February 25. Published in final edited form as: OBM Genet. 2018 ; 2(4): . doi:10.21926/obm.genet.1804045. The Relationship between Pneumocystis Infection in Animal and Human Hosts, and Climatological and Environmental Air Pollution Factors: A Systematic Review Robert F. Miller1,2,3,4,*, Laurence Huang5,6, and Peter D. Walzer7 1.Centre for Clinical Research in Infection and Sexual Health, Institute for Global Health, University College London, London WC1E 6JB, UK 2.Clinical Research Department, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK 3.Bloomsbury Clinic, Mortimer Market Centre, Central & North West London NHS Foundation Trust, London WC1E 6JB, UK 4.HIV Services, Royal Free London NHS Foundation Trust, London NW3 2QG, UK 5.Division of Pulmonary and Critical Care Medicine, Zuckerberg San Francisco General
[Show full text]
26Ypv8xo9426.Pdf
Originally published as: Ina Tammer, Kathrin Tintelnot, Rüdiger C. Braun-Dullaeus, Christian Mawrin, Cordula Scherlach, Dirk Schlüter, Wolfgang König, Infections due to Pseudallescheria/Scedosporium species in patients with advanced HIV disease — a diagnostic and therapeutic challenge, International Journal of Infectious Diseases, Volume 15, Issue 6, June 2011, Pages e422-e429, ISSN 1201-9712. DOI: 10.1016/j.ijid.2011.03.004 This is an author manuscript. The definitive version is available at: http://www.sciencedirect.com/ Infections due to Pseudallescheria/Scedosporium species in patients with advanced HIV disease — a diagnostic and therapeutic challenge Ina Tammera, Kathrin Tintelnotb, Rüdiger C. Braun-Dullaeusc, Christian Mawrind, Cordula Scherlache, Dirk Schlütera, Wolfgang Königa a Institute of Medical Microbiology, Otto-von-Guericke University, Leipziger Str. 44, 39 120 Magdeburg, Germany b Division of Mycology, Robert Koch Institute, Berlin, Germany c Internal Medicine, Department of Cardiology, Angiology, and Pneumology, Otto- von-Guericke University, Magdeburg, Germany d Institute of Neuropathology, Otto-von-Guericke University, Magdeburg, Germany e Institute of Neuroradiology, Otto-von-Guericke University, Magdeburg, Germany Summary Objectives: The aim of this study is to highlight the importance of infections caused by members of the genera Pseudallescheria/Scedosporium in HIV-positive patients. Methods: We describe a case of a fatal scedosporiosis in a treatment-naïve HIV patient and review all previously reported cases of pseudallescheriosis/scedosporiosis from a search of the PubMed and Deutsches Institut für Medizinische Dokumentation und Information (DIMDI) databases, applying the terms ‘Pseudallescheria’, ‘Scedosporium’, ‘Allescheria’, ‘Monosporium’, ‘Petriellidium’, ‘boydii’, ‘prolificans’, ‘inflatum’, cross-referenced with ‘HIV’ and ‘AIDS’. Results: Detection of Scedosporium and Pseudallescheria species has been reported in 22 HIV- positive patients.
[Show full text]
Inositol Polyphosphate Kinases, Fungal Virulence and Drug Discovery
Journal of Fungi Review Inositol Polyphosphate Kinases, Fungal Virulence and Drug Discovery Cecilia Li 1, Sophie Lev 1, Adolfo Saiardi 2, Desmarini Desmarini 1, Tania C. Sorrell 1,3,4 and Julianne T. Djordjevic 1,3,4,* 1 Centre for Infectious Diseases and Microbiology, The Westmead Institute for Medical Research, The University of Sydney, Westmead, NSW 2145, Australia; [email protected] (C.L.); [email protected] (S.L.); [email protected] (D.D.); [email protected] (T.C.S.) 2 Medical Research Council Laboratory for Molecular Cell Biology, University College London, London WC1E 6BT, UK; [email protected] 3 Marie Bashir Institute for Infectious Diseases and Biosecurity, University of Sydney, Westmead, NSW 2145, Australia 4 Westmead Hospital, Westmead, NSW 2145, Australia * Correspondence: [email protected]; Tel.: +61-2-8627-3420 Academic Editor: Maurizio Del Poeta Received: 22 July 2016; Accepted: 30 August 2016; Published: 6 September 2016 Abstract: Opportunistic fungi are a major cause of morbidity and mortality world-wide, particularly in immunocompromised individuals. Developing new treatments to combat invasive fungal disease is challenging given that fungal and mammalian host cells are eukaryotic, with similar organization and physiology. Even therapies targeting unique fungal cell features have limitations and drug resistance is emerging. New approaches to the development of antifungal drugs are therefore needed urgently. Cryptococcus neoformans, the commonest cause of fungal meningitis worldwide, is an accepted model for studying fungal pathogenicity and driving drug discovery. We recently characterized a phospholipase C (Plc1)-dependent pathway in C. neoformans comprising of sequentially-acting inositol polyphosphate kinases (IPK), which are involved in synthesizing inositol polyphosphates (IP).
[Show full text]